NCT07800754Recruiting
A Study in Greece Observing How Patients With Stomach and Esophageal Cancer Are Diagnosed and Treated in Everyday Medical Practice
Epidemiological Characteristics And Management Strategies Of Gastric/Gastrophaegal Junction Cancer Patients In Routine Clinical Practice: A Greek Multicenter Observational Study (The GRACE Study)
Source: ClinicalTrials.gov · Last updated 8 Oct 2026
Brief summary (registry, in English)
This is a retrospective-prospective observational, multicenter, single-country study aiming to describe the epidemiological characteristics and management strategies in patients with stage II-IVB gastric/GEJ adenocarcinoma in routine clinical practice in Greece.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 24 Aug 2026
- Start date
- 30 Sept 2026
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- AstraZeneca
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07800754
What you commit to
- Study type: Observational
- Planned participants: 300
- From 30 Sept 2026 to the primary completion date, 31 Dec 2027
- 6 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with another primary malignancy within the last 5 years, for which systemic anticancer treatment is required after the diagnosis of gastric/GEJ cancer.
Other
- Patients who participate or participated during the data collection period (prospective and retrospective) in any clinical investigation/clinical trial that includes interventions that fall outside the everyday clinical practice.
- Patients who have participated in the design and/or the conduct of the study.
Who the study is looking for
- Patients aged ≥18 years upon gastric/GEJ adenocarcinoma diagnosis.
- Written signed and dated informed consent by the patient (or their legally acceptable representative, as applicable). For deceased patients on the date of study entry a waiver of consent must be approved by the Hospital EC/IRB.
- Patients diagnosed with histologically confirmed, stage II to IVB adenocarcinoma of gastric/GEJ, between June 1st, 2025 and the end of the recruitment period (Q3 2027).
Age in the registry: 18 years to 130 years · Sex: All · Does not accept healthy volunteers
Sites (6)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Research Site Coordinator of this site? Confirm its status | Alexandroupoli | Greece | Not yet recruiting |
| Research Site Coordinator of this site? Confirm its status | Athens | Greece | Recruiting |
| Research Site Coordinator of this site? Confirm its status | Crete | Greece | Not yet recruiting |
| Research Site Coordinator of this site? Confirm its status | Ioannina | Greece | Not yet recruiting |
| Research Site Coordinator of this site? Confirm its status | Pátrai | Greece | Not yet recruiting |
| Research Site Coordinator of this site? Confirm its status | Thessaloniki | Greece | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.